What is a 503A compounding pharmacy, and how is it different from a 503B facility?
Section 503A generally addresses patient-specific compounding by a licensed pharmacist or physician. Section 503B creates an outsourcing-facility framework with FDA registration, current good manufacturing practice requirements, and additional oversight. Neither framework makes compounded drugs FDA approved. 1, 2
The distinction concerns how a compounder operates and which legal conditions it must meet. It is not a simple ranking of every product from one type of facility above every product from the other.
A patient should be able to identify the actual dispensing pharmacy, the preparation supplied, and how questions or quality concerns will be handled.
What is different about patient-specific prescriptions?
503A compounding generally requires a valid prescription for an identified patient, with limited anticipatory compounding conditions. A registered 503B outsourcing facility can compound under its framework without obtaining patient-specific prescriptions for every product in advance.
Does FDA registration mean a 503B product is approved?
No. Registration and inspection do not substitute for drug approval. Compounded preparations have not undergone FDA premarket review for safety, effectiveness, and quality.
What should I verify as a patient?
Confirm the pharmacy’s license and contact information, read the full label, and ask why the preparation is needed. The clinical rationale and applicable state rules remain relevant.
Bottom line
503A and 503B describe different regulatory pathways. Ask about the exact pharmacy and preparation, rather than relying on a label such as “FDA registered.”
See how Sipra weight care worksFrequently asked questions
Related questions
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From price shown is the 12-month plan rate. Prices may vary.
Was this helpful?